Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Written By Shannon Beyer

Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch.

Shannon Beyer
Previous

Nyxoah Appoints John Landry as Chief Financial Officer
Next

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer